한글목차

세계 방사선 치료 시장 규모는 2024년 72억 1,000만 달러에서 2030년에는 96억 2,000만 달러에 이르고, 예측 기간 동안 복합 연간 성장률(CAGR)은 4.9%가 될 것으로 예측됩니다.

방사선 치료 기술과 시스템의 기술적 진보는 예측 몇 년동안 시장 성장을 가속할 것으로 예상되는 주요 요인 중 하나입니다. 또한, 방사선 치료 제품의 높은 비용은 방사선 치료 시장의 성장에 영향을 미칩니다.

기술별로, 방사선 치료는 외부 빔 방사선 치료, 내부 빔 방사선 치료/브랙세라피로 구분됩니다. 또한 선형, 입자 방사선 치료, 전통적인 코발트 60 원격 요법으로 나뉩니다.

절차별로 방사선 치료 시장은 외부 빔 방사선 치료(EBRT) 절차와 내부 빔 방사선 치료(IBRT)/브랙세라피 절차로 구분됩니다. 외부 빔 방사선 치료는 종양 타겟팅의 정확성과 정확성이 향상되기 때문에 성장이 예상됩니다.

최종 사용자별로 병원과 독립 방사선치료센터로 구분됩니다.의 주요 용도와 큰 수요, 신흥 국가에서 병원 수 증가로 인한 것입니다.

본 보고서에서는 세계의 방사선 치료 시장에 대해 조사했으며, 시스템별, 소프트웨어 및 서비스별, 기술별, 용도별, 절차별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 소개
• 시장 역학
• 규제 분석
• 상환 시나리오
• 밸류체인 분석
• 공급망 분석
• 생태계 분석
• Porter's Five Forces 분석
• 주요 이해관계자와 구매 기준
• 무역 분석
• 특허 분석
• 가격 분석
• 기술 분석
• 사례 연구 분석
• 2024년-2025년의 주된 회의와 이벤트
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 투자와 자금조달 시나리오
• 언멧 요구
• 생성형 AI가 방사선 치료 시장에 미치는 영향

제6장 방사선 치료 시장 : 시스템별, 소프트웨어 및 서비스별

• 소개
• 시스템
• 소프트웨어 및 서비스

제7장 방사선 치료 시장 : 기술별

• 소개
• 외부 조사 방사선 치료 기술
• 내부 조사 방사선 치료/근접 방사선 치료

제8장 방사선 치료 시장 : 용도별

• 소개
• 외부 조사 방사선 치료
• 내부 조사 방사선 치료/근접 조사 요법

제9장 방사선 치료 시장 : 수기별

• 소개
• 외부 조사 방사선 치료
• 내부 조사 방사선 치료/근접 방사선 치료

제10장 방사선 치료 시장 : 최종사용자별

• 소개
• 병원
• 독립계 방사선 치료 센터

제11장 방사선 치료 시장 : 지역별

• 소개
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시 경제 전망
  • 독일
  • 프랑스
  • 영국
  • 스페인
  • 이탈리아
  • 기타
• 아시아태평양
  • 아시아태평양의 거시 경제 전망
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시 경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 중동 및 아프리카의 거시경제 전망
  • GCC 국가
  • 기타

제12장 경쟁 구도

• 소개
• 주요 진입기업의 전략/강점
• 수익 분석(2019년-2023년)
• 시장 점유율 분석(2023년)
• 기업평가 매트릭스 : 주요 진입기업(2023년)
• 기업평가 매트릭스 : 스타트업/중소기업(2023년)
• 기업평가와 재무지표
• 브랜드/제품 비교
• 경쟁 시나리오

제13장 기업 프로파일

• 주요 진출기업
  • SIEMENS HEALTHINEERS AG(VARIAN MEDICAL SYSTEMS, INC.)
  • ELEKTA
  • ACCURAY INCORPORATED
  • IBA WORLDWIDE
  • VIEWRAY, INC.
  • BRAINLAB AG
  • PERSPECTIVE THERAPEUTICS
  • HITACHI LTD.(HITACHI HIGH-TECH CORPORATION)
  • SUMITOMO HEAVY INDUSTRIES, LTD.
  • CARL ZEISS MEDITEC AG(WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG)
  • MIM SOFTWARE INC.
  • PANACEA MEDICAL TECHNOLOGIES PVT. LTD.
  • PROVISION HEALTHCARE
  • MEVION MEDICAL SYSTEMS
  • RAYSEARCH LABORATORIES
  • KONINKLIJKE PHILIPS NV
• 기타 기업
  • INTRAOP MEDICAL, INC.
  • OPTIVUS PROTON THERAPY, INC.
  • BEBIG MEDICAL
  • P-CURE
  • THERAGENICS CORPORATION
  • PROTOM INTERNATIONAL
  • DOS ISOFT SA
  • ISOAID, LLC
  • MAGNETTX ONCOLOGY SOLUTIONS LTD.

제14장 부록

영문목차

The global radiotherapy market is projected to reach USD 9.62 billion by 2030 from USD 7.21 billion in 2024, growing at a CAGR of 4.9% during the forecast period. The technological advancements of radiotherapy technologies and systems is one of the major factors anticipated to boost market growth in the forecasting years. Additionally, the high cost of radiotherapy products affects the growth of the radiotherapy market.

"The external beam radiotherapy segment to hold the largest share of the market in 2024."

Based on technology, radiotherapy is segmented into external beam radiotherapy, internal beam radiotherapy/ brachytherapy. The external beam radiotherapy segment is expected to dominate the radiotherapy market during the forecast period. The external beam radiotherapy segment is further divided into LINACs, Particle therapy and Conventional cobalt-60 teletherapy. With the growing prevalence of cancer, system and software enhancements, and the increasing adoption of external beam radiotherapy devices worldwide leads to the growth of this market segment.

"The external beam radiotherapy procedures segment to hold the largest share of the market in 2024."

Based on procedure, the Radiotherapy market is segmented into external beam radiotherapy (EBRT) procedures and internal beam radiotherapy (IBRT)/brachytherapy procedures. The radiotherapy market is expected to be dominated by external beam radiotherapy procedures segment during the forecast period. The external beam radiotherapy procedures are expected to grow due to increased precision & accuracy of tumor targeting in this therapy..

"The hospitals companies segment to hold the largest share of the market in 2024."

The end user market is segmented into hospitals and independent radiotherapy centres. Hospitals accounted for the largest share of the global radiotherapy market in 2023 during the forecasted years. This can be attributed to the major applications and large demand of radiotherapy accounted by hospital sector and the growing number of hospitals in emerging countries.

"The market in the APAC region is expected to register highest growth rate for Radiotherapy in 2024."

The radiotherapy market covers five key geographies-North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for radiotherapy was held by the market in the North American region, comprising the US and Canada. On the other hand, the Asia Pacific market is estimated to register the highest growth rate during the forecast period. The increasing market penetration opportunities in emerging APAC countries led to the growth of the radiotherapy market in this region.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1- 48%, Tier 2- 36%, and Tier 3- 16%
• By Designation: Directors- 14%, C-level- 10%, and Others- 76%
• By Region: North America- 40%, Europe- 32%, Asia Pacific- 20%, Latin America- 5%, MEA- 3%

The prominent players in the Radiotherapy market are Siemens Healthineers GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA WORLDWIDE (Belgium), ViewRay Technologies, Inc (US), Perspective Therapeutics, Inc. (US), Hitachi High Tech Corporation (Japan), Sumitomo Heavy Industries Ltd. (Japan), Carl Zeiss Meditec AG (Germany), Koninklijke Philips N.V. (Netherlands), among others.

Research Coverage

This report studies the radiotherapy market based on system, software & service, technology, application, procedure, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

• Analysis of key drivers (Advancements in radiotherapy treatment technology, Growing patient population, Increasing initiatives to promote radiotherapy awareness, Growing use of particle therapy for cancer treatment), restraints (High cost of advanced lab consumables, Environmental sustainability concerns), opportunities (Lack of adequate healthcare infrastructure, High capital cost of radiotherapy, Complexity of radiotherapy), and challenges (Dearth of skilled personnel, Difficulties in visualizing tumors during radiotherapy, Risk of Radiation Exposure) influencing the growth of the radiotherapy market
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the radiotherapy market
• Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service developments in the radiotherapy market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the radiotherapy market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and services of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONS CONSIDERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 List of secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
  • 2.2.2 USAGE-BASED MARKET ESTIMATION
  • 2.2.3 PRIMARY RESEARCH VALIDATION
• 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
• 2.4 RESEARCH ASSUMPTIONS
  • 2.4.1 STUDY ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 RADIOTHERAPY MARKET OVERVIEW
• 4.2 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
• 4.3 EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE AND REGION (2022)
• 4.4 RADIOTHERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.5 RADIOTHERAPY MARKET: REGIONAL MIX, 2022-2030 (USD MILLION)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Advancements in radiotherapy treatment
    • 5.2.1.2 Growing patient population
    • 5.2.1.3 Increasing initiatives to promote radiotherapy awareness
    • 5.2.1.4 Growing use of particle therapy for cancer treatment
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Lack of adequate healthcare infrastructure
    • 5.2.2.2 High capital cost of radiotherapy
    • 5.2.2.3 Complexity of radiotherapy
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emerging economies
    • 5.2.3.2 Favorable changes in US radiotherapy payment model
    • 5.2.3.3 Government and private investments to meet rising demand for cancer treatment
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Dearth of skilled personnel
    • 5.2.4.2 Difficulties in visualizing tumors during radiotherapy
    • 5.2.4.3 Risk of radiation exposure
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
  • 5.3.2 REGULATORY LANDSCAPE
    • 5.3.2.1 North America
      • 5.3.2.1.1 US
      • 5.3.2.1.2 Canada
    • 5.3.2.2 Europe
    • 5.3.2.3 Asia Pacific
      • 5.3.2.3.1 China
      • 5.3.2.3.2 Japan
      • 5.3.2.3.3 India
• 5.4 REIMBURSEMENT SCENARIO
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 RESEARCH & DEVELOPMENT
  • 5.5.2 PROCUREMENT & PRODUCT DEVELOPMENT
  • 5.5.3 MARKETING, SALES, AND DISTRIBUTION
• 5.6 SUPPLY CHAIN ANALYSIS
  • 5.6.1 PROMINENT COMPANIES
  • 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
  • 5.6.3 END USERS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8.2 BARGAINING POWER OF SUPPLIERS
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 THREAT OF SUBSTITUTES
  • 5.8.5 THREAT OF NEW ENTRANTS
• 5.9 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.9.2 KEY BUYING CRITERIA
• 5.10 TRADE ANALYSIS
  • 5.10.1 IMPORT DATA
  • 5.10.2 EXPORT DATA
• 5.11 PATENT ANALYSIS
• 5.12 PRICING ANALYSIS
  • 5.12.1 AVERAGE SELLING PRICE, BY PRODUCT
  • 5.12.2 AVERAGE SELLING PRICE, BY COUNTRY
• 5.13 TECHNOLOGY ANALYSIS
  • 5.13.1 KEY TECHNOLOGIES
    • 5.13.1.1 Linear accelerators (LINACs)
    • 5.13.1.2 Image-guided radiotherapy (IGRT)
    • 5.13.1.3 Intensity-modulated radiotherapy (IMRT)
    • 5.13.1.4 Particle therapy
    • 5.13.1.5 Surface-guided radiotherapy (SGRT)
  • 5.13.2 COMPLEMENTARY TECHNOLOGIES
    • 5.13.2.1 Chemotherapy
    • 5.13.2.2 Immunotherapy
    • 5.13.2.3 Hyperthermia therapy
  • 5.13.3 ADJACENT TECHNOLOGIES
    • 5.13.3.1 Medical imaging technologies
    • 5.13.3.2 Radioisotope production technologies
    • 5.13.3.3 Systematic radiotherapy
    • 5.13.3.4 Theranostics
• 5.14 CASE STUDY ANALYSIS
• 5.15 KEY CONFERENCES & EVENTS, 2024-2025
• 5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.17 INVESTMENT & FUNDING SCENARIO
• 5.18 UNMET NEEDS
• 5.19 IMPACT OF GENERATIVE AI ON RADIOTHERAPY MARKET

6 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE

• 6.1 INTRODUCTION
• 6.2 SYSTEMS
  • 6.2.1 CONTINUOUS DEVELOPMENT OF ADVANCED TECHNOLOGIES TO BOOST MARKET
• 6.3 SOFTWARE & SERVICES
  • 6.3.1 INCREASING DEMAND FOR PRECISE AND EFFECTIVE CANCER TREATMENT TO SUPPORT MARKET GROWTH

7 RADIOTHERAPY MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES
  • 7.2.1 LINACS
    • 7.2.1.1 Conventional LINACs
      • 7.2.1.1.1 Long treatment duration to limit adoption
    • 7.2.1.2 Stereotactic advanced electron/cobalt-60 LINACs
      • 7.2.1.2.1 CyberKnife
        • 7.2.1.2.1.1 Precise radiation delivery with robotic correction capabilities to drive market
      • 7.2.1.2.2 Gamma Knife
        • 7.2.1.2.2.1 Ongoing product development and launches to support growth
      • 7.2.1.2.3 TomoTherapy
        • 7.2.1.2.3.1 High installation and maintenance costs to limit adoption
    • 7.2.1.3 MRI LINACs
      • 7.2.1.3.1 Real-time imaging advantage to propel growth
  • 7.2.2 PARTICLE THERAPY
    • 7.2.2.1 Cyclotrons
      • 7.2.2.1.1 Enhanced outcomes and other advantages to boost adoption
    • 7.2.2.2 Synchrotrons
      • 7.2.2.2.1 Increasing investments in synchrotron facilities to drive market
    • 7.2.2.3 Synchrocyclotrons
      • 7.2.2.3.1 High space requirements to limit widespread adoption
  • 7.2.3 CONVENTIONAL COBALT-60 TELETHERAPY
    • 7.2.3.1 Complex dose delivery planning and radiation exposure to limit market adoption
• 7.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY
  • 7.3.1 SEEDS
    • 7.3.1.1 Adverse side-effects associated with seeds to limit adoption
  • 7.3.2 AFTERLOADERS
    • 7.3.2.1 Proper positioning and better control of isotopes in modern afterloaders to drive demand
  • 7.3.3 IORT SYSTEMS
    • 7.3.3.1 Rising adoption of electronic brachytherapy procedures to support growth
  • 7.3.4 APPLICATORS
    • 7.3.4.1 High risk of radiation exposure in manual applicators to limit growth

8 RADIOTHERAPY MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS
  • 8.2.1 PROSTATE CANCER
    • 8.2.1.1 High incidence rate and efficiency of EBRT in prostate cancer treatment to support growth
  • 8.2.2 BREAST CANCER
    • 8.2.2.1 Therapeutic benefits of EBRT to drive market
  • 8.2.3 LUNG CANCER
    • 8.2.3.1 High prevalence of lung cancer and efficiency of EBRT to drive market
  • 8.2.4 HEAD & NECK CANCER
    • 8.2.4.1 Noninvasive treatment of head & neck cancers to drive market
  • 8.2.5 COLORECTAL CANCER
    • 8.2.5.1 High incidence of colorectal cancer to support market growth
  • 8.2.6 OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS
• 8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS
  • 8.3.1 PROSTATE CANCER
    • 8.3.1.1 Precision of brachytherapy to drive market
  • 8.3.2 GYNECOLOGICAL CANCER
    • 8.3.2.1 Availability of alternatives to hinder adoption of brachytherapy
  • 8.3.3 BREAST CANCER
    • 8.3.3.1 Wide usage as replacement for traditional EBRT to drive market
  • 8.3.4 CERVICAL CANCER
    • 8.3.4.1 Effectiveness of combined brachytherapy-chemotherapy procedures to support adoption
  • 8.3.5 PENILE CANCER
    • 8.3.5.1 Rising awareness and effectiveness of brachytherapy to drive market
  • 8.3.6 OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS

9 RADIOTHERAPY MARKET, BY PROCEDURE

• 9.1 INTRODUCTION
• 9.2 EXTERNAL BEAM RADIOTHERAPY
  • 9.2.1 IMAGE-GUIDED RADIOTHERAPY
    • 9.2.1.1 Growing demand in treating deep-seated tumors to drive market
  • 9.2.2 INTENSITY-MODULATED RADIOTHERAPY
    • 9.2.2.1 Advantages over 2D and 3D-CRT to boost adoption
  • 9.2.3 3D CONFORMAL RADIOTHERAPY
    • 9.2.3.1 High precision and minimal damage to nearby tissues to boost adoption
  • 9.2.4 STEREOTACTIC RADIOTHERAPY
    • 9.2.4.1 Minimally invasive procedure to drive end-user preference
  • 9.2.5 PARTICLE THERAPY
    • 9.2.5.1 High usage as primary mode of cancer treatment to sustain market growth
  • 9.2.6 OTHER EXTERNAL BEAM RADIOTHERAPY PROCEDURES
• 9.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY
  • 9.3.1 LDR BRACHYTHERAPY
    • 9.3.1.1 Low risk of radiation exposure to surrounding tissues to drive adoption
  • 9.3.2 HDR BRACHYTHERAPY
    • 9.3.2.1 Possibility of tissue injury to affect adoption
  • 9.3.3 PDR BRACHYTHERAPY
    • 9.3.3.1 Combination of advantages to boost growth

10 RADIOTHERAPY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 HOSPITALS TO DOMINATE END-USER MARKET
• 10.3 INDEPENDENT RADIOTHERAPY CENTERS
  • 10.3.1 LOWER OPERATING COSTS AND CONVENIENCE TO SUPPORT MARKET GROWTH

11 RADIOTHERAPY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Changes in reimbursement scenario to drive growth
  • 11.2.3 CANADA
    • 11.2.3.1 Favorable initiatives from government and private organizations to boost market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Availability of novel radiotherapy products to drive market
  • 11.3.3 FRANCE
    • 11.3.3.1 Presence of advanced healthcare system to augment growth
  • 11.3.4 UK
    • 11.3.4.1 High incidence of cancer to drive market
  • 11.3.5 SPAIN
    • 11.3.5.1 Growing research activities on cancer care to promote growth
  • 11.3.6 ITALY
    • 11.3.6.1 Rising clinical trials and research activities in hospitals and universities to support growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Rising geriatric population to encourage growth
  • 11.4.3 CHINA
    • 11.4.3.1 Growing partnerships among market players to support growth
  • 11.4.4 INDIA
    • 11.4.4.1 Increasing preference for minimally invasive treatment to propel market
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Increasing incidence of cancer to support market
  • 11.4.6 AUSTRALIA
    • 11.4.6.1 Growing cancer cases to fuel market
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Increasing prevalence of cancer to fuel market
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising target population to boost market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Booming medical tourism to expedite growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RADIOTHERAPY MARKET
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.4.1 EXTERNAL BEAM RADIOTHERAPY MARKET RANKING
  • 12.4.2 INTERNAL BEAM RADIOTHERAPY MARKET RANKING
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Technology footprint
    • 12.5.5.3 Application footprint
    • 12.5.5.4 End-user footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.)
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services/Solutions offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
      • 13.1.1.3.2 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 ELEKTA
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services/Solutions offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches and approvals
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 ACCURAY INCORPORATED
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services/Solutions offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product approvals
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 IBA WORLDWIDE
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services/Solutions offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Products launches
      • 13.1.4.3.2 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 VIEWRAY, INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services/Solutions offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product approvals
      • 13.1.5.3.2 Deals
  • 13.1.6 BRAINLAB AG
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services/Solutions offered
  • 13.1.7 PERSPECTIVE THERAPEUTICS
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services/Solutions offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION)
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services/Solutions offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
  • 13.1.9 SUMITOMO HEAVY INDUSTRIES, LTD.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services/Solutions offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches
      • 13.1.9.3.2 Other developments
  • 13.1.10 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG)
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services/Solutions offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Products launches
  • 13.1.11 MIM SOFTWARE INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services/Solutions offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches and approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services/Solutions offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches and approvals
  • 13.1.13 PROVISION HEALTHCARE
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services/Solutions offered
  • 13.1.14 MEVION MEDICAL SYSTEMS
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services/Solutions offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches
      • 13.1.14.3.2 Deals
  • 13.1.15 RAYSEARCH LABORATORIES
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services/Solutions offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches
      • 13.1.15.3.2 Deals
  • 13.1.16 KONINKLIJKE PHILIPS N.V.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products/Services/Solutions offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product launches
      • 13.1.16.3.2 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 INTRAOP MEDICAL, INC.
  • 13.2.2 OPTIVUS PROTON THERAPY, INC.
  • 13.2.3 BEBIG MEDICAL
  • 13.2.4 P-CURE
  • 13.2.5 THERAGENICS CORPORATION
  • 13.2.6 PROTOM INTERNATIONAL
  • 13.2.7 DOS ISOFT SA
  • 13.2.8 ISOAID, LLC
  • 13.2.9 MAGNETTX ONCOLOGY SOLUTIONS LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS